South Korea’s Samsung Bioepis and Biogen (Nasdaq: BIIB) today announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab).
Lucentis was developed by the Roche (ROG: SIX) unit Genentech, which markets the product in the USA, while marketing rights elsewhere are held by Novartis (NOVN: VX), and generated sale of $401 million in the second-quarter of 2020 for the Swiss giant.
Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness. If approved, SB11 will join a growing number of biosimilars developed by Samsung Bioepis, a joint venture between South Korea’s Samsung BioLogics and US biotech major Biogen and commercialized by Biogen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze